Abingworth Announces Leadership Transition and Appointments

Leadership Changes - Kurt von Emster transitions from Head of Abingworth Life Sciences to Managing Partner, focusing on clinical co-development investments and supporting venture investments [1] - Dr. Bali Muralidhar is appointed as the new Head of Abingworth Life Sciences and Chief Investment Officer [1] - Travis Wilson joins as Managing Director, concentrating on clinical co-development and life sciences buyout opportunities [1] Company Background - Abingworth is a leading transatlantic life sciences investment firm and part of Carlyle, having invested in over 185 life science companies since 1973 [3] - The firm has facilitated over 50 mergers and acquisitions and more than 75 IPOs [3] - Abingworth's investments are categorized into seed and early-stage, development stage, and clinical co-development [3] Carlyle Overview - Carlyle is a global investment firm with $474 billion in assets under management as of September 30, 2025 [4] - The firm operates across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest [4] - Carlyle employs over 2,400 people in 27 offices worldwide [4]